左乙拉西坦对阿尔茨海默病或轻度认知障碍患者认知效果的系统评价

IF 1.5 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

Current Therapeutic Research-clinical and Experimental Pub Date : 2025-01-01 DOI:10.1016/j.curtheres.2025.100798

Mohamad Hosein Mohamadi MD , Amir Bavafa PhD , Sahar Salehi PhD , Mahsa Abedi MSc , Fahimeh Shahabi MSc , Sana Jafarlou MD , Pirhossein Kolivand PhD , Sajad Sahab-Negah PhD

{"title":"左乙拉西坦对阿尔茨海默病或轻度认知障碍患者认知效果的系统评价","authors":"Mohamad Hosein Mohamadi MD , Amir Bavafa PhD , Sahar Salehi PhD , Mahsa Abedi MSc , Fahimeh Shahabi MSc , Sana Jafarlou MD , Pirhossein Kolivand PhD , Sajad Sahab-Negah PhD","doi":"10.1016/j.curtheres.2025.100798","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Various therapeutic interventions have been investigated for cognitive impairment, a common problem in Alzheimer’s disease (AD). Levetiracetam (LEV), an antiepileptic drug, has been shown to alleviate cognitive impairment.</div></div><div><h3>Objective</h3><div>The present systematic review aimed to evaluate the cognitive effects of LEV in patients with AD or mild cognitive impairment (MCI).</div></div><div><h3>Methods</h3><div>We searched PubMed/MEDLINE, Scopus, Web of Sciences, and Embase databases for all studies on LEV and cognitive impairment. After multistep screening, we identified qualified interventional studies and performed further data extraction. We reviewed the methodological diversity across the studies and assessed the quality of each study using the critical appraisal of the Joanna Briggs Institute checklist (the risk of bias assessment).</div></div><div><h3>Results</h3><div>Of the 1091 publications, only 5 articles were qualified for review. All studies enrolled patients with AD or MCI, and at least 1 arm of the trial involved LEV therapy. Four of 5 studies reported significant cognitive improvement in patients with AD or MCI after the LEV trials, whereas 1 study found no significant change in cognitive status. The risk of bias assessment revealed that 4 studies had a low risk of bias. Among them, 3 showed significant improvement, whereas 1 did not report a significant change in cognitive function.</div></div><div><h3>Conclusions</h3><div>The efficacy of LEV therapy for cognitive impairment varies across studies owing to different methodologies, dosages, treatment durations, and outcome assessment tools. This study suggests that LEV may exert a beneficial impact on cognitive function in patients with AD or MCI. However, a quantitative comparison or meta-analysis is essential to draw definitive conclusions about the cognitive effects of LEV in AD and MCI.</div></div>","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"103 ","pages":"Article 100798"},"PeriodicalIF":1.5000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Cognitive Effect of Levetiracetam in Patients with Alzheimer’s Disease or Mild Cognitive Impairment: A Systematic Review\",\"authors\":\"Mohamad Hosein Mohamadi MD , Amir Bavafa PhD , Sahar Salehi PhD , Mahsa Abedi MSc , Fahimeh Shahabi MSc , Sana Jafarlou MD , Pirhossein Kolivand PhD , Sajad Sahab-Negah PhD\",\"doi\":\"10.1016/j.curtheres.2025.100798\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Various therapeutic interventions have been investigated for cognitive impairment, a common problem in Alzheimer’s disease (AD). Levetiracetam (LEV), an antiepileptic drug, has been shown to alleviate cognitive impairment.</div></div><div><h3>Objective</h3><div>The present systematic review aimed to evaluate the cognitive effects of LEV in patients with AD or mild cognitive impairment (MCI).</div></div><div><h3>Methods</h3><div>We searched PubMed/MEDLINE, Scopus, Web of Sciences, and Embase databases for all studies on LEV and cognitive impairment. After multistep screening, we identified qualified interventional studies and performed further data extraction. We reviewed the methodological diversity across the studies and assessed the quality of each study using the critical appraisal of the Joanna Briggs Institute checklist (the risk of bias assessment).</div></div><div><h3>Results</h3><div>Of the 1091 publications, only 5 articles were qualified for review. All studies enrolled patients with AD or MCI, and at least 1 arm of the trial involved LEV therapy. Four of 5 studies reported significant cognitive improvement in patients with AD or MCI after the LEV trials, whereas 1 study found no significant change in cognitive status. The risk of bias assessment revealed that 4 studies had a low risk of bias. Among them, 3 showed significant improvement, whereas 1 did not report a significant change in cognitive function.</div></div><div><h3>Conclusions</h3><div>The efficacy of LEV therapy for cognitive impairment varies across studies owing to different methodologies, dosages, treatment durations, and outcome assessment tools. This study suggests that LEV may exert a beneficial impact on cognitive function in patients with AD or MCI. However, a quantitative comparison or meta-analysis is essential to draw definitive conclusions about the cognitive effects of LEV in AD and MCI.</div></div>\",\"PeriodicalId\":10920,\"journal\":{\"name\":\"Current Therapeutic Research-clinical and Experimental\",\"volume\":\"103 \",\"pages\":\"Article 100798\"},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Therapeutic Research-clinical and Experimental\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0011393X25000232\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Therapeutic Research-clinical and Experimental","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0011393X25000232","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

摘要

认知障碍是阿尔茨海默病（AD）的一个常见问题，人们已经研究了各种治疗干预措施。左乙拉西坦（LEV）是一种抗癫痫药物，已被证明可以减轻认知障碍。目的评价LEV对AD或轻度认知障碍（MCI）患者认知功能的影响。方法检索PubMed/MEDLINE、Scopus、Web of Sciences和Embase数据库中所有关于LEV和认知障碍的研究。经过多步筛选，我们确定了合格的介入研究，并进行了进一步的数据提取。我们回顾了研究方法的多样性，并使用乔安娜布里格斯研究所清单（偏见风险评估）的关键评估来评估每项研究的质量。结果1091篇文献中，仅有5篇符合评审条件。所有的研究都纳入了AD或MCI患者，并且至少有一个组的试验涉及LEV治疗。5项研究中有4项报告了LEV试验后AD或MCI患者的认知能力有显著改善，而1项研究发现认知状态没有显著变化。偏倚风险评估显示，4项研究偏倚风险较低。其中3例有明显改善，1例认知功能无明显改变。由于不同的方法、剂量、治疗持续时间和结果评估工具，LEV治疗认知障碍的疗效在不同的研究中存在差异。本研究提示LEV可能对AD或MCI患者的认知功能产生有益影响。然而，定量比较或荟萃分析对于得出关于LEV对AD和MCI的认知影响的明确结论至关重要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Cognitive Effect of Levetiracetam in Patients with Alzheimer’s Disease or Mild Cognitive Impairment: A Systematic Review

Background

Various therapeutic interventions have been investigated for cognitive impairment, a common problem in Alzheimer’s disease (AD). Levetiracetam (LEV), an antiepileptic drug, has been shown to alleviate cognitive impairment.

Objective

The present systematic review aimed to evaluate the cognitive effects of LEV in patients with AD or mild cognitive impairment (MCI).

Methods

We searched PubMed/MEDLINE, Scopus, Web of Sciences, and Embase databases for all studies on LEV and cognitive impairment. After multistep screening, we identified qualified interventional studies and performed further data extraction. We reviewed the methodological diversity across the studies and assessed the quality of each study using the critical appraisal of the Joanna Briggs Institute checklist (the risk of bias assessment).

Results

Of the 1091 publications, only 5 articles were qualified for review. All studies enrolled patients with AD or MCI, and at least 1 arm of the trial involved LEV therapy. Four of 5 studies reported significant cognitive improvement in patients with AD or MCI after the LEV trials, whereas 1 study found no significant change in cognitive status. The risk of bias assessment revealed that 4 studies had a low risk of bias. Among them, 3 showed significant improvement, whereas 1 did not report a significant change in cognitive function.

Conclusions

The efficacy of LEV therapy for cognitive impairment varies across studies owing to different methodologies, dosages, treatment durations, and outcome assessment tools. This study suggests that LEV may exert a beneficial impact on cognitive function in patients with AD or MCI. However, a quantitative comparison or meta-analysis is essential to draw definitive conclusions about the cognitive effects of LEV in AD and MCI.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Current Therapeutic Research-clinical and Experimental 医学-药学

CiteScore

3.50

自引率

0.00%

发文量

审稿时长

3 months

期刊介绍： We also encourage the submission of manuscripts presenting preclinical and very preliminary research that may stimulate further investigation of potentially relevant findings, as well as in-depth review articles on specific therapies or disease states, and applied health delivery or pharmacoeconomics. CTR encourages and supports the submission of manuscripts describing: • Interventions designed to understand or improve human health, disease treatment or disease prevention; • Studies that focus on problems that are uncommon in resource-rich countries; • Research that is "under-published" because of limited access to monetary resources such as English language support and Open Access fees (CTR offers deeply discounted English language editing); • Republication of articles previously published in non-English journals (eg, evidence-based guidelines) which could be useful if translated into English; • Preclinical and clinical product development studies that are not pursued for further investigation based upon early phase results.